In a report released on September 15, Jason Kolbert from Dawson James maintained a Hold rating on Check-Cap (CHEK – Research Report). The company’s shares closed last Friday at $0.31.
According to TipRanks, Kolbert is an analyst with an average return of -2.4% and a 35.31% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Can-Fite BioPharma, Sorrento Therapeutics, and Daré Bioscience.
Currently, the analyst consensus on Check-Cap is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $1.31 and a one-year low of $0.29. Currently, Check-Cap has an average volume of 495.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Read More on CHEK:
